Benchmark lowered the firm’s price target on Clene (CLNN) to $31 from $33 and keeps a Buy rating on the shares. Having obtained agreement from the FDA regarding the statistical analysis plan, Clene continues to work toward an anticipated NDA submission in Q4 for CNM-Au-8 in the treatment of ALS, the analyst noted while updating the firm’s model.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLNN:
- Clene Expands Equity Distribution to Raise Capital
- Clene files to sell 491,496 shares of common stock for holders
- Clene’s CNM-Au8 Shows Promise in Parkinson’s Treatment, Justifying Buy Rating
- Clene presents preclinical data supporting CNM-Au8 for Parkinson’s disease
- Clene price target lowered to $48 from $83 at Canaccord